At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 282 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Tirzepatide and Dulaglutide for Type 2 Diabetes. Completed, enrolled 282 participants across 38 sites in 5 countries.
Detailed Summary
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesBelgium, Germany, Mexico, Romania, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartNov 2022
Primary CompletionJul 2024
Study CompletionAug 2024
TodayJul 2026
First PostedOct 3, 2022
Enrollment StartNov 30, 2022
Primary CompletionJul 15, 2024
Study CompletionAug 12, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.7 years ago
Interventions
Tirzepatidedrug
Administered SC
Dulaglutidedrug
Administered SC